Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, New Report Launched

The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.

In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.

The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.

The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.
• About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 71 pages, “Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists” report covering the Selective GLP-1 Analogs for Metabolic Diseases, Selective GLP-1 Analogs for Non-Metabolic Diseases, Dual Target GLP-1 Analogs, Corporate GLP-1 Receptor Agonist R&D Pipelines. The report covered few companies are - Addex Therapeutics, Aegis Therapeutics, Alteogen, Amunix, Arisaph Pharmaceuticals, Arisgen, AstraZeneca (MedImmune), Boehringer Ingelheim, Camurus, ConjuChem, Dong-A Pharmaceutical (Dong-A Socio Holding), Eli Lilly

For more information see - http://mrr.cm/Z7R